Company History | Company Information | KYORIN Pharmaceutical Co., Ltd.

1923	Toyo Shinyaku Sha, the predecessor of KYORIN Pharmaceutical Co., Ltd., was founded.
1931	Kyorin Chemical Laboratory was established.
1940	The company was renamed KYORIN Pharmaceutical Co., Ltd., and Kyorin Yakuhin Co., Ltd. was organized as an independent marketing division.
1946	The Okaya Plant was started; and the Tokyo, Osaka and Nagoya Branches were opened.
1957	The medical journal bulletin "Doctor Salon" was started.
1961	BEHYD, a diuretic and anti-hypertensive agent, was launched.
1962	Kyorin Chemical Laboratory (later: Technical Center of Development) was established.
1965	KYORIN AP-2, an analgesic, was launched DEAMELIN-S, an oral hypoglycemic agent, was launched. The head office was completed in the place.
1967	The nogi Plant was started.(now closed)
1971	CHOLEXAMIN, a lipid metabolism and peripheral circulation improving agent, was launched.
1974	HESPANDER, a plasma substitute and extracorporeal circulation flow improver, was launched.
1976	Hydroxyethylstarch (HES) was licensed out to Pfrimmer (Germany, present Baxter Deutschland).
1977	Central Research Laboratories(present Discovery Research Laboratories) were established.
1980	Norfloxacin (NFLX), an antibacterial agent, was licensed to Merck & Co., Inc. (USA).
1981	MUCODYNE, mucoregulants, was launched.
1982	NFLX was licensed to Astra (UK, present Astrazeneca) and Boots (UK, present BASF).
1983	NFLX was licensed to American Home Products (USA).
1984	BACCIDAL (NFLX), a broad-spectrum oral antibacterial agent, was launched.
1986	Fleroxacin (FLRX), an antibacterial agent, was licensed to F.Hoffmann-La Roche (Switzerland). APLACE, an agent for gastritis & gastric ulcer, was launched.
1989	KETAS, for bronchial asthma & cerebrovascular disorders, was launched. BACCIDAL Eye-drops, a broad-spectrum ophthalmic antibacterial agent, was launched.
1991	BACCIDAL Tablet for Children was launched.
1992	KYORIN Pharmaceutical Co., Ltd. and Kyorin Yakuhin Co., Ltd. were merged and the new KYORIN Pharmaceutical Co., Ltd. was founded.
1993	MEGALOCIN (FLRX), a long active new quinolone agent, was launched.
1995	Research Center (now Development Research Laboratories) was founded by integrating Research Center of Organic Syntheses, Technical Center of Development, Technical Center of Product Formulation and Technical Center of Safety Assessment. The noshiro Plant was started
1996	A joint venture, Nisshin KYORIN Pharmaceutical Co., Ltd., was established with Kyorin's capital participation. Gatifloxacin was licensed to Bristol-Myers Squibb (USA).
1998	MILTON an effervescent disinfectant business was acquired from P&G.
1999	The company's stock was issued on the Tokyo Stock Exchange, Second Section.
2000	The company's stock was issued on the Tokyo Stock Exchange, First Section. Gatifloxacin-eyedrops was licensed to Allergan(USA).
2001	KIPRES, the leukotriene receptor antagonist and bronchial asthma treatment medicine, was launched. A subsidiary company "Kyorin USA, Inc."(USA) was established.
2002	A subsidiary company "Kyorin Europe GmbH"(Germany) was established. GATIFLO(GFLX), a broad-spectrum,oral antibacterial agent, was launched.
2004	ActivX Biosciences, Inc. became a wholly owned subsidiary.
2005	The stocks of Toyo Pharmar Co., Ltd. (present KYORIN Rimedio Co., Ltd.) were acquired, making it into a subsidiary company. Dr. Program Co., Ltd. became a wholly owned subsidiary.
2006	The Kyorin group shifts to a holding company structure through a share exchange with KYORIN Co., Ltd. (currently KYORIN Holdings, Inc.) (KYORIN Pharmaceutical Co., Ltd. is delisted, and KYORIN Co., Ltd. is listed on the First Section of the Tokyo Stock Exchange market.) The new Noshiro Plant began operating.
2007	A business transfer agreement was made with the Fresenius Kabi AG Group in Germany concerning Hespander and Salinhes, plasma substitutes and hemodilution agents. Uritos Tablets 0.1mg, an overactive bladder drug, was launched. Kipres Oral Granules 4mg, a bronchial asthma treatment drug, was launched.
2008	Kipres Tablets 5mg, a bronchial asthma and allergic rhinitis treatment drug, was launched. KYORIN Pharmaceutical merged with Nissin Kyorin Pharmaceutical. Ulcerative colitis and crohn’s disease therapeutic agent Pentasa Tablets 500 was launched.
2009	Marketing rights in China were granted to Senju Pharmaceutical for Gatifloxacin Ophthalmic Solution. A license agreement for Neramexane, a tinnitus drug, was made with Merz Pharmaceuticals for the Japan region.
2010	KYORIN Co., Ltd. changed its name to KYORIN Holdings, Inc. Mucodyne DS50%, a mucoregulant, was launched.
2011	A license agreement for Aclidinium Bromide, a COPD drug, was made with Almirall for the Japan region. Uritos Orally Disintegrating (OD) Tablets 0.1mg, an overactive bladder drug, was launched.